Erratum

Serine 207 phosphorylated lysyl-tRNA synthetase predicts disease-free survival of non-small-cell lung carcinoma (Oncotarget (2017) 8 (65186-65198) DOI:10.18632/oncotarget.18053)

Suliman Boulos, Min Chul Park, Marian Zeibak, Shen Yun Foo, Yoon Kyung Jeon, Young Tae Kim, Alex Motzik, Sagi Tshori, Tamar Hamburger, Sunghoon Kim, Hovav Nechushtan, Ehud Razin

Research output: Contribution to journalComment/debateResearch

Abstract

Figure 5: Subgroup analysis of nuclear P207 LysRS according to Lymph nodes positivity. Disease free survival of wild-type EGFR patients with (positive) or without (negative) cytosolic (A) and nuclear (B) LysRS. Disease free survival of mutated EGFR patients with (positive) or without (negative) cytosolic (C) and nuclear (D) LysRS.

Original languageEnglish
Number of pages1
JournalOncotarget
Volume9
Issue number90
StatePublished - 1 Nov 2018

Fingerprint

Lysine-tRNA Ligase
Non-Small Cell Lung Carcinoma
Serine
Disease-Free Survival
Lymph Nodes

Cite this

Boulos, Suliman ; Park, Min Chul ; Zeibak, Marian ; Foo, Shen Yun ; Jeon, Yoon Kyung ; Kim, Young Tae ; Motzik, Alex ; Tshori, Sagi ; Hamburger, Tamar ; Kim, Sunghoon ; Nechushtan, Hovav ; Razin, Ehud. / Erratum : Serine 207 phosphorylated lysyl-tRNA synthetase predicts disease-free survival of non-small-cell lung carcinoma (Oncotarget (2017) 8 (65186-65198) DOI:10.18632/oncotarget.18053). In: Oncotarget. 2018 ; Vol. 9, No. 90.
@article{7bc93d29b27d495d8019bcf7dca3388d,
title = "Erratum: Serine 207 phosphorylated lysyl-tRNA synthetase predicts disease-free survival of non-small-cell lung carcinoma (Oncotarget (2017) 8 (65186-65198) DOI:10.18632/oncotarget.18053)",
abstract = "Figure 5: Subgroup analysis of nuclear P207 LysRS according to Lymph nodes positivity. Disease free survival of wild-type EGFR patients with (positive) or without (negative) cytosolic (A) and nuclear (B) LysRS. Disease free survival of mutated EGFR patients with (positive) or without (negative) cytosolic (C) and nuclear (D) LysRS.",
author = "Suliman Boulos and Park, {Min Chul} and Marian Zeibak and Foo, {Shen Yun} and Jeon, {Yoon Kyung} and Kim, {Young Tae} and Alex Motzik and Sagi Tshori and Tamar Hamburger and Sunghoon Kim and Hovav Nechushtan and Ehud Razin",
year = "2018",
month = "11",
day = "1",
language = "English",
volume = "9",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals LLC",
number = "90",

}

Erratum : Serine 207 phosphorylated lysyl-tRNA synthetase predicts disease-free survival of non-small-cell lung carcinoma (Oncotarget (2017) 8 (65186-65198) DOI:10.18632/oncotarget.18053). / Boulos, Suliman; Park, Min Chul; Zeibak, Marian; Foo, Shen Yun; Jeon, Yoon Kyung; Kim, Young Tae; Motzik, Alex; Tshori, Sagi; Hamburger, Tamar; Kim, Sunghoon; Nechushtan, Hovav; Razin, Ehud.

In: Oncotarget, Vol. 9, No. 90, 01.11.2018.

Research output: Contribution to journalComment/debateResearch

TY - JOUR

T1 - Erratum

T2 - Serine 207 phosphorylated lysyl-tRNA synthetase predicts disease-free survival of non-small-cell lung carcinoma (Oncotarget (2017) 8 (65186-65198) DOI:10.18632/oncotarget.18053)

AU - Boulos, Suliman

AU - Park, Min Chul

AU - Zeibak, Marian

AU - Foo, Shen Yun

AU - Jeon, Yoon Kyung

AU - Kim, Young Tae

AU - Motzik, Alex

AU - Tshori, Sagi

AU - Hamburger, Tamar

AU - Kim, Sunghoon

AU - Nechushtan, Hovav

AU - Razin, Ehud

PY - 2018/11/1

Y1 - 2018/11/1

N2 - Figure 5: Subgroup analysis of nuclear P207 LysRS according to Lymph nodes positivity. Disease free survival of wild-type EGFR patients with (positive) or without (negative) cytosolic (A) and nuclear (B) LysRS. Disease free survival of mutated EGFR patients with (positive) or without (negative) cytosolic (C) and nuclear (D) LysRS.

AB - Figure 5: Subgroup analysis of nuclear P207 LysRS according to Lymph nodes positivity. Disease free survival of wild-type EGFR patients with (positive) or without (negative) cytosolic (A) and nuclear (B) LysRS. Disease free survival of mutated EGFR patients with (positive) or without (negative) cytosolic (C) and nuclear (D) LysRS.

UR - http://www.scopus.com/inward/record.url?scp=85056994589&partnerID=8YFLogxK

M3 - Comment/debate

VL - 9

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 90

ER -